Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Fig. 5

Modelled OS compared to observational datasets. MCL, mantle cell lymphoma; OS, overall survival; SEER, Surveillance, Epidemiology, and End Results Program; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone; VR-CAP, bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us